Dear Sir, After the publication of the article by Ver-resen et al. [1] and others [2], including our own report [3], the clinical intensity of anaphylactoid reactions described in the literature has been very diverse. The majority of the reactions described have been serious (ana-phylactic shock, severe dyspnea, broncho-spasm) although minor reactions can occur as seen in our case. It would be interesting to correlate the clinical symptoms with the type and dosage of ACE inhibitor used. The results probably would indicate extreme variability between individuals, more in relation with the ACE inhibitors than with the type of membrane used, although most of the descriptions relate the AN69 membrane with this reactions. From this point of view, the pathogenic hypothesis proposed by Tielemans et al.
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